ANAPTYSBIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21 USD | +11.29% |
|
+5.69% | -1.96% |
| Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
| Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
Financials (USD)
| Sales 2024 * | 16.39M | Sales 2025 * | 25.59M | Capitalization | 516M |
|---|---|---|---|---|---|
| Net income 2024 * | -178M | Net income 2025 * | -196M | EV / Sales 2024 * | 14.2 x |
| Net cash position 2024 * | 283M | Net cash position 2025 * | 316M | EV / Sales 2025 * | 7.8 x |
| P/E ratio 2024 * |
-2.99
x | P/E ratio 2025 * |
-3.22
x | Employees | 117 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on AnaptysBio, Inc.
More recommendations
More press releases
| 1 day | +11.29% | ||
| 1 week | +6.82% | ||
| Current month | -6.75% | ||
| 1 month | -1.78% | ||
| 3 months | -11.84% | ||
| 6 months | +28.44% | ||
| Current year | -1.96% |
1 week
18.49
21.61
1 month
18.4925.62
Current year
18.4927.50
1 year
13.3627.50
3 years
13.3637.89
5 years
10.0079.09
10 years
10.00134.00
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Faga
CEO | Chief Executive Officer | 44 | 21-11-25 |
Dennis Mulroy
DFI | Director of Finance/CFO | 69 | 20-07-14 |
Paul Lizzul
CTO | Chief Tech/Sci/R&D Officer | 49 | 20-07-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hollings Renton
BRD | Director/Board Member | 77 | 15-06-29 |
Dennis Fenton
BRD | Director/Board Member | 72 | 18-03-04 |
Magda Marquet
BRD | Director/Board Member | 65 | 21-01-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 0 M€ | 0.00% | - | |
| 0.07% | 0 M€ | 0.00% | - | |
| 0.02% | 509 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 21 | +11.29% | 649,412 |
| 24-04-25 | 18.87 | -2.08% | 401,012 |
| 24-04-24 | 19.27 | +0.47% | 385,671 |
| 24-04-23 | 19.18 | -2.44% | 387,321 |
| 24-04-22 | 19.66 | -1.06% | 139,714 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
18.87
USD
Average target price
43.5
USD
Spread / Average Target
+130.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.96% | 516M | |
| -2.31% | 103B | |
| +0.56% | 95.71B | |
| +1.69% | 22.02B | |
| -17.37% | 20.9B | |
| -9.30% | 17.85B | |
| -41.01% | 16.21B | |
| -14.85% | 15.52B | |
| +3.21% | 13.86B | |
| +33.54% | 12.04B |
- Stock Market
- Equities
- ANAB Stock
